Drug Trial Radar · NCT04615273
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Dec 3, 2020
Primary completion
Nov 2, 2023
Study completion Dec 1, 2023
Sponsor
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/SIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 23 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily somatropin product). This is a global trial conducted in, but not limited to, the United States, Europe, and Asia.
Conditions
- Growth Hormone Deficiency
- Endocrine System Diseases
- Hormone Deficiency
Interventions
LonapegsomatropinDrug
Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
PlaceboOther
The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.
SomatropinDrug
Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Trunk Percent Fat at Week 38Time frame: Baseline, Week 38
Locations
113 sites in 24 countries. Site status is shown where the registry gives one.
Ascendis Pharma Investigational Site
Birmingham, Alabama
Ascendis Pharma Investigational Site
Phoenix, Arizona
Ascendis Pharma Investigational Site
Fresno, California
Ascendis Pharma Investigational Site
Los Angeles, California
Ascendis Pharma Investigational Site
Los Angeles, California
Ascendis Pharma Investigational Site
Palo Alto, California
Ascendis Pharma Investigational Site
Torrance, California
Ascendis Pharma Investigational Site
Chicago, Illinois
Ascendis Pharma Investigational Site
Indianapolis, Indiana
Ascendis Pharma Investigational Site
Boston, Massachusetts
Ascendis Pharma Investigational Site
Dearborn, Michigan
Ascendis Pharma Investigational Site
Rochester, Minnesota
Ascendis Pharma Investigational Site
St Louis, Missouri
Ascendis Pharma Investigational Site
Las Vegas, Nevada
Ascendis Pharma Investigational Site
Reno, Nevada
Ascendis Pharma Investigational Site
New York, New York
Ascendis Pharma Investigational Site
New York, New York
Ascendis Pharma Investigational Site
Morehead City, North Carolina
Ascendis Pharma Investigational Site
Portland, Oregon
Ascendis Pharma Investigational Site
Pittsburgh, Pennsylvania
Ascendis Pharma Investigational Site
Dallas, Texas
Ascendis Pharma Investigational Site
San Antonio, Texas
Ascendis Pharma Investigational Site
Seattle, Washington
Ascendis Pharma Investigational Site
Yerevan, Armenia
Ascendis Pharma Investigational Site
Saint Leonards, New South Wales, Australia
Ascendis Pharma Investigational Site
Sydney, New South Wales, Australia
Ascendis Pharma Investigational Site
Box Hill, Victoria, Australia
Ascendis Pharma Investigational Site
Fitzroy, Victoria, Australia
Ascendis Pharma Investigational Site
Parkville, Victoria, Australia
Ascendis Pharma Investigational Site
Perth, Western Australia, Australia
Ascendis Pharma Investigational Site
Vancouver, British Columbia, Canada
Ascendis Pharma Investigational Site
Halifax, Nova Scotia, Canada
Ascendis Pharma Investigational Site
Copenhagen, Denmark
Ascendis Pharma Investigational Site
Lyon, France
Ascendis Pharma Investigational Site
Marseille, France
Ascendis Pharma Investigational Site
Nantes, France
Ascendis Pharma Investigational Site
Paris, France
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
München, Bavaria, Germany
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.